The agreement generates revenues of approximately SEK 29 million of which SEK 27 million is to be recognized during the second half of 2026.

The feasibility study

In the feasibility study, Prolight evaluated 260 patient samples from BRAINBox´s FDA Pivotal Study set on the Psyros point-of-care (POC) platform using three assays for traumatic brain injury (TBI). The results demonstrated excellent performance. The outcome supports an expanded collaboration and represents an important step toward BRAINBox’s planned FDA clearance process. Regulatory approval of the BRAINBox system would also mark the U.S. market approval of the Psyros platform, representing a key milestone for Prolight.

The development agreement

The development agreement covers the development of advanced multiplex cartridges, software and the initial purchase of pilot instruments.
 
“The expansion of our collaboration with BRAINBox represents a strong validation of the Psyros platform. The agreement provides funded development and near‑term revenues, while advancing our multiplex capabilities. It also enables us to progress the platform in a capital‑efficient manner together with a strong partner,” says Ulf Bladin, CEO of Prolight Diagnostics.
 
 
The TBI program represents both a major commercial opportunity and a source of near-term revenue, while reinforcing the broader applicability of the Psyros platform beyond the cardiovascular area, the company states.